BRKR Share Price Performance
US$45.13
-12.05 (-21.07%)
7.6% undervalued intrinsic discount
US$48.83
Fair Value
Price US$45.13
AnalystConsensusTarget US$48.83
AnalystLowTarget US$38.50
AnalystHighTarget US$65.58
Fair ValueUS$48.83
Share Pricen/a
Bruker Corporation Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 31 Fair Values set on narratives written by author
BRKR Community Narratives
AN
Fair Value US$48.83 7.6% undervalued intrinsic discount
BRKR: Recent Upgrade Will Drive Confidence In Core Market Resilience
0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
AN
Fair Value US$38 18.8% overvalued intrinsic discount
Falling Funding Will Depress Revenues But Cost Cuts Help Margins
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$63.51 28.9% undervalued intrinsic discount
Growing Global Health R&D Investment Will Boost Diagnostic Demand
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
BRKR: Recent Upgrade Will Drive Confidence In Core Market Resilience
Key Takeaways Recovery in biopharma funding and innovation pipeline will drive future growth, while recurring revenue streams improve earnings stability and net margins. Cost reduction programs and secular demand for analytical solutions strengthen profitability, even in a challenging revenue environment.Read more
0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
AN
US$48.83
7.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
3.55% p.a.
Profit Margin
6.44%
Future PE
38.45x
Price in 2028
US$61.93
Falling Funding Will Depress Revenues But Cost Cuts Help Margins
Key Takeaways Heavy reliance on academic and government research funding poses structural risks, especially amid major budget cuts in key markets. Market expansion and innovation efforts face challenges from regulatory hurdles, price competition, and a shift toward lower-cost analytical solutions.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$38
18.8% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
2.38% p.a.
Profit Margin
12.17%
Future PE
16.3x
Price in 2028
US$48.17
Growing Global Health R&D Investment Will Boost Diagnostic Demand
Key Takeaways Product innovation, expanded diagnostics offerings, and delayed global R&D investments position Bruker for outsized growth and higher margins across core and emerging markets. Increasing service, software, and consumables revenues enhance earnings resilience, driving future margin expansion and supporting stable, long-term profitability.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$63.51
28.9% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
3.99% p.a.
Profit Margin
11.61%
Future PE
27.24x
Price in 2028
US$80.52
Trending Discussion
Recently Updated Narratives
AN
BRKR: Constructive Bookings And Rating Upgrades Will Support Stable Forward Expectations
Fair Value: US$48.83 7.6% undervalued intrinsic discount
15 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Falling Funding Will Depress Revenues But Cost Cuts Help Margins
Fair Value: US$38 18.8% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Growing Global Health R&D Investment Will Boost Diagnostic Demand
Fair Value: US$63.51 28.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Bruker Corporation Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.16
- 48.83%
- -0.69%
- 81.5%
About BRKR
- Founded
- 1960
- Employees
- 11396
- CEO
- WebsiteView website
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper platform for bacterial and fungal identification and establish, DNA test strips, and; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was founded in 1960 and is headquartered in Billerica, Massachusetts.
